Table 1.
Baseline characteristics, n (%)
| Baseline characteristics | |
| Total number of graft failure | 329 (100) |
| Female gender | 127 (39) |
| Mean age at the time of transplant (yr) | 42.2 ± 13.7 |
| Caucasian | 253 (77) |
| Causes of end stage renal disease: | |
| Glomerulonephritis | 99 (30) |
| Diabetes | 71 (22) |
| Hypertension | 35 (11) |
| Polycystic kidney disease | 34 (10) |
| Congenital disorder | 9 (3) |
| Other | 81 (25) |
| Mean number of transplants (Range 1-3) | 1.29 ± 0.59 |
| Living donor transplant | 108 (33) |
| Induction Immunosuppression: | |
| Basiliximab | 179 (54) |
| Thymoglobulin | 52 (16) |
| Alemtuzumab | 66 (20) |
| Other | 32 (10) |
| Organ failure method: | |
| Resumption of dialysis | 319 (97) |
| Re-transplantation (preemptive re-transplant) | 10 (3) |
| DSA within a year prior to the graft failure: | |
| Present | 184 (56) |
| Absent | 89 (27) |
| Not tested | 56 (17) |
| Mean graft survival (yr) | 4.9 ± 4.4 |
| Mean interval between biopsy and graft failure (d) | 106.5 ± 104.6 |
DSA: Donor-specific antibodies.